|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�����ۺ��� |
|
��� |
|
�����쳣 |
|
��Ƥϸ�� |
|
ϸ������ |
| ��������������� | |
|
�� |
|
���� |
|
������ |
| PubMed | |
|
Article by ZUO Fu-guo |
|
Article by JIN Chun-lin |
|
Article by LI Tie-nan |
�����ۺ��������ķ��ӻ����о���չ
��, ����, ������
�����е�������ҽԺƤ����, 110003
�����ۺ��������߽鵼��,��Ѫ����Ϊ�����Ķ�ϵͳ�Լ�����ĿǰΪֹ,�����ۺ�����ȷ�з������Ʋ���,���������Ŵ�������,��Ⱦ�������������ۺ��������õĽ����Th1ϸ���鵼�����߷�Ӧ��Ѫ����Ƥϸ�����ܲ�������������ϸ�������쳣�����ز����˰����ۺ����ķ������̡�
An Update on Molecular Mechanism in the Pathogenesis of Behcet's disease
Department of Dermatology, the Seventh People's Hospital of Shenyang, Shenyang 110003, China
Department of Dermatology, the Seventh People's Hospital of Shenyang, Shenyang 110003, China
Behcet's disease is an immune-mediated multi-systemic vasculitis. The pathogenesis of the disease is still unclear. It may result from comprehensive action of multiple factors, including genetic and environmental factors, infections and immune abnormality. This paper is a review on the molecular mechanism in the pathogenesis of this disease.
[2] Mizuki N,Ota M,Katsuyama Y,et al.Sequencing-based typing of HLA-B*51 alleles and the significant association of HLA-B*5101 and-B*5108 with Behcet's disease in Greek patients.Tissue Antigens,2002,59:118-121.
[3] Paul M,Klein T,Krause I,et al.Allelic distribution of HLA-B*5 in HLA-BS-positive Israeli patients with Behcet's disease.Tissue Antigens,2001,58:185-186.
[4] Kotter I,Gunaydin I,Stubiger N,et al.Comparative analysis of the association of HLA-B*51 suballeles with Behcet's disease in patients of German and Turkish origin.Tissue Antigens,2001,58:166-170.
[5] Mizuki N,Ota M,Katsuyama Y,et al.HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behcet's disease.Tissue Antigens,2001,58:181-184.
[6] Park SH,Park KS,Seo YI,et al.Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behcet's disease.J Korean Med Sci,2002,17:366-370.
[7] Kaya TI,Dur H,Tursen U,et al.Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behcet's disease.Clin Exp Dermatol,2002,27:498-501.
[8] Gul A,Hajeer AH,Worthington J,et al.Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23.Arthritis Rheum,2001,44:2693-2696.
[9] Touitou I,Magne X,Molinari N,et al.MEFV mutations in Behcet's disease.Hum Mutat,2000,16:271-272.
[10] Polat G,Eskandari G,Kaya TI,et al.Association of the platelet glycoprotein Ia C807T/G873A gene polymorphism and thrombosis in Behcet patients.Haematologia (Budap),2002,32:121-128.
[11] Kim JU,Chang HK,Lee SS,et al.Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease and rheumatic diseases with vasculitis.Ann Rheum Dis,2003,62:1083-1087.
[12] Kim EH,Mok JW,Bang DS,et al.Intercellular adhesion molecule1 polymorphisms in Korean patients with Behcet s disease.J Korean Med Sci,2003,18:415-418.
[13] Cho ML,Kim JY,Ko HJ,et al.The MCP-1 promoter-2518 polymorphism in Behcet's disease:correlation between allele types,MCP-1 production and clinical symptoms among Korean patients.Autoimmunity,2004,37:77-80.
[14] Tasci B,Direskeneli H,Serdaroglu P,et al.Humoral immune response to mycobacterial heat shock protein (hsp)65 in the cerebrospinal fluid of neuro-Behcet patients.Clin Exp Immunol,1998,113:100-104.
[15] Hamzaoui K,Hamzaoui A,Guemira F,et al.Cytokine profile in Behcet's disease patients.Relationship with disease activity.Scand J Rheumatol,2002,31:205-210.
[16] Li B,Yang P,Zhou H,et al.T-bet expression is upregulated in active Behcet's disease.Br J Ophthalmol,2003,87:1264-1267.
[17] Triolo G,Accardo-Palumbo A,Dieli F,et al.Humoral and cell mediated immune response to cow's milk proteins in Behcet's disease.Ann Rheum Dis,2002,61:459-462.
[18] Ertenli I,Kiraz S,Celik IC,et al.Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus:effect on the prethrombotic state.Ann Rheum Dis,2001,60:1149-1151.
[19] Cekmen M,Evereklioglu C,Er H,et al.Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome.Int J Dermatol,2003,42:870-875.
[20] Saglam K,Yilmaz MI,Saglam A,et al.Levels of circulating intercellular adhesion molecule-1 in patients with Behcet's disease.Rheumatol Iht,2002,21:146-148.
[21] Evereklioglu C,Turkoz Y,Er H,et al.Increased nitric oxide production in patients with Behcet's disease:is it a new activity marker? J Am Acad Dermatol,2002,46:50-54.
[22] Karakuzu A,Aktas A,Akcay F.Serum E-selectin and beta 2-microglobulin levels in Behcet's disease.J Int Med Res,2002,30:85-88.
[23] Yang P,Chen L,Zhou H,et al.Resistance of lymphocytes to Fasmediated apoptosis in Behcet's disease and Vogt-Koyangi-Harada syndrome.Ocul Immunol Inflamm,2002,10:47-52.
[24] Wakisaka S,Takeba Y,Mihara S,et al.Aberrant Fas ligand expression in lymphocytes in patients with Behcet's disease.Int Arch Allergy Immunol,2002,129:175-180.
[25] Senturk N,Yildiz L,Sullu Y,et al.Expression of bcl-2 protein in active skin lesions of Behcet's disease.Int J Dermatol,2001,40:747-750.
[26] Sullu Y,Senturk N,Yildiz L,et al.Bcl-2 expression in skin pathergy reaction of Behcet's disease.Dermatology,2001,202:90-93.